侵入式脑机接口开启临床，企业已收到上千名瘫痪患者请求

Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - The BCI technology primarily targets patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis (ALS) [4]. - Several companies, including Shanghai Ladder Medical Technology, Beijing Chip Intelligence, and Hangzhou Jialiang Medical, are developing BCI devices and have announced clinical research plans [4]. Group 2: Patient Outcomes and Training - Initial results from the first patient implanted with an invasive BCI showed that after 2-3 weeks of training, the patient could perform tasks like playing chess and racing games, achieving a level of control similar to that of a healthy individual [3]. - The BCI system allows for two modes: outputting information from the brain to control external devices and inputting information to the brain for sensory restoration [3]. Group 3: Future Prospects and Challenges - Companies have received thousands of requests from paralyzed patients seeking participation in clinical trials, indicating a high demand for BCI technology [6][8]. - The development of BCI devices for treating epilepsy is expected to progress more rapidly, with nearly 100 patients already implanted and data being prepared for product approval [8]. - Experts emphasize the importance of focusing on the effectiveness of BCI devices for patients rather than solely on rapid commercialization [9].